Ono Pharmaceutical Co., Ltd. (OPHLY)
USD 3.79
(1.61%)
USD 3.79
(1.61%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 6.55 Billion JPY | 0.0% |
| 2023 | 6.67 Billion JPY | 2.72% |
| 2022 | 6.5 Billion JPY | -7.52% |
| 2021 | 7.03 Billion JPY | 13.88% |
| 2020 | 6.17 Billion JPY | 249.75% |
| 2019 | 1.76 Billion JPY | 451.56% |
| 2018 | 320 Million JPY | -40.96% |
| 2017 | 542 Million JPY | 5.24% |
| 2016 | 515 Million JPY | 62.46% |
| 2015 | 317 Million JPY | -32.26% |
| 2014 | 468 Million JPY | 249.25% |
| 2013 | 134 Million JPY | 1118.18% |
| 2012 | 11 Million JPY | -8.33% |
| 2011 | 12 Million JPY | -14.29% |
| 2010 | 14 Million JPY | -6.67% |
| 2009 | 15 Million JPY | -11.76% |
| 2008 | 17 Million JPY | -5.56% |
| 2007 | 18 Million JPY | -10.0% |
| 2006 | 20 Million JPY | -76.19% |
| 2005 | 84 Million JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 6.32 Billion JPY | 0.0% |
| 2024 Q2 | 6.63 Billion JPY | 0.0% |
| 2024 Q1 | 6.95 Billion JPY | 0.0% |
| 2024 FY | 6.55 Billion JPY | -1.89% |
| 2024 Q4 | 6.55 Billion JPY | 0.0% |
| 2023 FY | 6.67 Billion JPY | 2.72% |
| 2023 Q4 | 6.67 Billion JPY | 3.44% |
| 2023 Q3 | 6.45 Billion JPY | 6.17% |
| 2023 Q2 | 6.08 Billion JPY | -4.64% |
| 2023 Q1 | 6.37 Billion JPY | -1.91% |
| 2022 Q1 | 6.91 Billion JPY | -1.58% |
| 2022 FY | 6.5 Billion JPY | -7.52% |
| 2022 Q4 | 6.5 Billion JPY | -3.93% |
| 2022 Q3 | 6.76 Billion JPY | -2.69% |
| 2022 Q2 | 6.95 Billion JPY | 0.51% |
| 2021 Q2 | 7.25 Billion JPY | 25.03% |
| 2021 Q1 | 5.8 Billion JPY | -5.95% |
| 2021 Q3 | 7.07 Billion JPY | -2.52% |
| 2021 FY | 7.03 Billion JPY | 13.88% |
| 2021 Q4 | 7.03 Billion JPY | -0.65% |
| 2020 Q3 | 6.61 Billion JPY | -0.06% |
| 2020 FY | 6.17 Billion JPY | 249.75% |
| 2020 Q1 | 6.47 Billion JPY | 266.63% |
| 2020 Q2 | 6.62 Billion JPY | 2.3% |
| 2020 Q4 | 6.17 Billion JPY | -6.7% |
| 2019 Q2 | 470 Million JPY | 35.45% |
| 2019 Q1 | 347 Million JPY | 8.44% |
| 2019 Q3 | 1.83 Billion JPY | 290.21% |
| 2019 FY | 1.76 Billion JPY | 451.56% |
| 2019 Q4 | 1.76 Billion JPY | -3.76% |
| 2018 Q4 | 320 Million JPY | -11.85% |
| 2018 Q2 | 416 Million JPY | -11.11% |
| 2018 Q1 | 468 Million JPY | -13.65% |
| 2018 FY | 320 Million JPY | -40.96% |
| 2018 Q3 | 363 Million JPY | -12.74% |
| 2017 FY | 542 Million JPY | 5.24% |
| 2017 Q4 | 542 Million JPY | -14.1% |
| 2017 Q3 | 631 Million JPY | 5.87% |
| 2017 Q2 | 596 Million JPY | 9.16% |
| 2017 Q1 | 546 Million JPY | 6.02% |
| 2016 Q4 | 515 Million JPY | 5.32% |
| 2016 Q3 | 489 Million JPY | 8.43% |
| 2016 Q1 | 341 Million JPY | 7.57% |
| 2016 FY | 515 Million JPY | 62.46% |
| 2016 Q2 | 451 Million JPY | 32.26% |
| 2015 Q2 | 366 Million JPY | -6.87% |
| 2015 FY | 317 Million JPY | -32.26% |
| 2015 Q1 | 393 Million JPY | -16.03% |
| 2015 Q4 | 317 Million JPY | -5.93% |
| 2015 Q3 | 337 Million JPY | -7.92% |
| 2014 Q3 | 52 Million JPY | -37.35% |
| 2014 Q2 | 83 Million JPY | -23.85% |
| 2014 FY | 468 Million JPY | 249.25% |
| 2014 Q1 | 109 Million JPY | -18.66% |
| 2014 Q4 | 468 Million JPY | 800.0% |
| 2013 Q4 | 134 Million JPY | -16.25% |
| 2013 Q1 | 11 Million JPY | 0.0% |
| 2013 FY | 134 Million JPY | 1118.18% |
| 2013 Q3 | 160 Million JPY | -13.51% |
| 2013 Q2 | 185 Million JPY | 1581.82% |
| 2012 Q3 | 11 Million JPY | 0.0% |
| 2012 Q1 | 12 Million JPY | 0.0% |
| 2012 Q4 | 11 Million JPY | 0.0% |
| 2012 FY | 11 Million JPY | -8.33% |
| 2012 Q2 | 11 Million JPY | -8.33% |
| 2011 Q2 | 13 Million JPY | -7.14% |
| 2011 FY | 12 Million JPY | -14.29% |
| 2011 Q3 | 13 Million JPY | 0.0% |
| 2011 Q4 | 12 Million JPY | -7.69% |
| 2011 Q1 | 14 Million JPY | 0.0% |
| 2010 Q2 | 14 Million JPY | 0.0% |
| 2010 FY | 14 Million JPY | -6.67% |
| 2010 Q4 | 14 Million JPY | 0.0% |
| 2010 Q3 | 14 Million JPY | 0.0% |
| 2009 Q4 | 15 Million JPY | -6.25% |
| 2009 FY | 15 Million JPY | -11.76% |
| 2009 Q3 | 16 Million JPY | 0.0% |
| 2008 FY | 17 Million JPY | -5.56% |
| 2007 FY | 18 Million JPY | -10.0% |
| 2006 FY | 20 Million JPY | -76.19% |
| 2005 FY | 84 Million JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 70.663% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 82.841% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -6020.047% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 67.296% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -33687.31% |